Literature DB >> 22212439

Analysis of various etiologies of hypertension in patients hospitalized in the endocrinology division.

Dan Ye1, FengQin Dong, XunLiang Lu, Zhe Zhang, YunFei Feng, ChengJiang Li.   

Abstract

This research aimed to analyze the clinical data of various etiologies of hypertension in patients hospitalized in the Endocrinology Division. The differences between essential and secondary hypertension were examined to provide a basis for clinical differential diagnosis. The data from all the inpatients with hypertension of unknown origin admitted in the Endocrinology Division of the First Affiliated Hospital of the Zhejiang University School of Medicine from January 2001 to May 2011 were reviewed. The patients were classified into either essential or secondary hypertensive groups. The differentiating parameters of these forms of hypertension were analyzed using the one-factor and multi-factor logistic regression analysis. A total of 1,001 cases were selected in which 346 cases (34.6%) were essential hypertensive and 655 cases (65.4%) were secondary hypertensive. Adrenal hypertension was the primary cause of secondary hypertension, followed by renal artery, central, psychogenic, and renal hypertension as well as others that have not been classified systematically. Using one-factor analysis, significant differences were found among duration of hypertension, age, the onset age, family history of hypertension, diastolic pressure on admission, Cushing syndrome, body mass index (BMI), urine protein, serum creatinine, orthostatic aldosterone, ratio of orthostatic aldosterone to renin activity, incidence of fatty liver displayed by type-B ultrasound, and computed tomography adrenal masses incidence (P < 0.05). Multi-factor regression analysis showed that family history of hypertension (OR = 7.196) and BMI above the normal range (OR = 15.124) were the independent factors that predicted essential hypertension, but failed to determine any other valid predictors of secondary causes except adrenal masses (OR = 10.114), orthostatic aldosterone value >200 pg/ml (OR = 9.742), and a ratio of orthostatic aldosterone and renin activity >40 (OR = 4.723).

Entities:  

Mesh:

Year:  2012        PMID: 22212439     DOI: 10.1007/s12020-011-9588-5

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  29 in total

Review 1.  Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis.

Authors:  Gilberta Giacchetti; Paolo Mulatero; Franco Mantero; Franco Veglio; Marco Boscaro; Francesco Fallo
Journal:  Trends Endocrinol Metab       Date:  2008-03-04       Impact factor: 12.015

2.  Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration.

Authors:  Ashraf H Ahmed; Richard D Gordon; Paul J Taylor; Gregory Ward; Eduardo Pimenta; Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2011-03-16       Impact factor: 5.958

3.  Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience.

Authors:  Abdurrahman Comlekci; Serkan Yener; Senem Ertilav; Mustafa Secil; Baris Akinci; Tevfik Demir; Levent Kebapcilar; Firat Bayraktar; Sena Yesil; Sevinc Eraslan
Journal:  Endocrine       Date:  2009-10-30       Impact factor: 3.633

4.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

Review 5.  Diagnosis of secondary hypertension: an age-based approach.

Authors:  Anthony J Viera; Dana M Neutze
Journal:  Am Fam Physician       Date:  2010-12-15       Impact factor: 3.292

6.  Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan.

Authors:  Masao Omura; Jun Saito; Kunio Yamaguchi; Yukio Kakuta; Tetsuo Nishikawa
Journal:  Hypertens Res       Date:  2004-03       Impact factor: 3.872

7.  Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents.

Authors:  Ebe D'Adamo; Anna M G Cali; Ram Weiss; Nicola Santoro; Bridget Pierpont; Veronika Northrup; Sonia Caprio
Journal:  Diabetes Care       Date:  2010-08       Impact factor: 17.152

8.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

9.  The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome.

Authors:  James W Findling; Hershel Raff; David C Aron
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

10.  Association between fatty acid binding protein 3 gene variants and essential hypertension in humans.

Authors:  Takahiro Ueno; Masayoshi Soma; Yasuharu Tabara; Katsushi Tokunaga; Kzunobu Tahira; Noboru Fukuda; Koichi Matsumoto; Tomohiro Nakayama; Tomohiro Katsuya; Toshio Ogihara; Yoshio Makita; Akira Hata; Michiko Yamada; Norio Takahashi; Nobuhito Hirawa; Satoshi Umemura; Tetsuro Miki
Journal:  Am J Hypertens       Date:  2008-04-10       Impact factor: 2.689

View more
  2 in total

Review 1.  Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features.

Authors:  Alberto Mazza; Michela Armigliato; Maria Cristina Marzola; Laura Schiavon; Domenico Montemurro; Giorgio Vescovo; Marco Zuin; Sotirios Chondrogiannis; Roberta Ravenni; Giuseppe Opocher; Patrick M Colletti; Domenico Rubello
Journal:  Endocrine       Date:  2013-07-02       Impact factor: 3.633

2.  Screening for secondary endocrine hypertension in young patients.

Authors:  Raluca Trifanescu; Mara Carsote; Andra Caragheorgheopol; Dan Hortopan; Anda Dumitrascu; Mariana Dobrescu; Catalina Poiana
Journal:  Maedica (Buchar)       Date:  2013-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.